Enzychem Lifesciences Corporation (KOSDAQ: 183490)

Market Cap	120.95B
Revenue (ttm)	82.07B
Net Income (ttm)	-7.86B
Shares Out	79.84M
EPS (ttm)	-94.96
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	129,100
Average Volume	207,290
Open	1,515.00
Previous Close	1,515.00
Day's Range	1,497.00 - 1,530.00
52-Week Range	1,047.00 - 2,220.00
Beta	1.44
RSI	63.25
Earnings Date	Mar 21, 2025

About Enzychem Lifesciences

Enzychem Lifesciences Corporation engages in developing novel small molecule therapeutics for patients with unmet needs for oncology, inflammatory, and severe respiratory diseases in South Korea. It is also developing EC-18, an oral small molecule for fibrotic diseases, such as nonalcoholic steatohepatitis; and in severe respiratory diseases as a potential therapy for COVID-19. The company was founded in 1999 and is headquartered in Seoul, South Korea.

• Industry: Pharmaceutical Preparations
• Founded: 1999
• Employees: 122
• Stock Exchange: KOSDAQ
• Ticker Symbol: 183490

Financial Performance

In 2023, Enzychem Lifesciences's revenue was 76.04 billion, an increase of 185.46% compared to the previous year's 26.64 billion. Losses were -9.33 billion, -62.59% less than in 2022.